A5101916159- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Molecular Biology Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Estrogen and related hormone effects
- RNA modifications and cancer
- Radiopharmaceutical Chemistry and Applications
- Redox biology and oxidative stress
- Retinoids in leukemia and cellular processes
- Renal cell carcinoma treatment
- Genetic and Kidney Cyst Diseases
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Hormonal and reproductive studies
- Sexual Differentiation and Disorders
- Cancer-related molecular mechanisms research
- Bladder and Urothelial Cancer Treatments
- Radiomics and Machine Learning in Medical Imaging
- Genomics and Chromatin Dynamics
- Cancer-related gene regulation
- Genetic factors in colorectal cancer
- Advanced Proteomics Techniques and Applications
- Chromatin Remodeling and Cancer
Stockholm South General Hospital
2025
Karolinska Institutet
2005-2025
Karolinska University Hospital
2000-2017
Peking University First Hospital
2017
Peking University
2017
Howard Hughes Medical Institute
2004
Louisiana State University Health Sciences Center New Orleans
2004
Linköping University Hospital
2004
Linköping University
2004
Stanford University
2004
Prostate cancer, a leading cause of cancer death, displays broad range clinical behavior from relatively indolent to aggressive metastatic disease. To explore potential molecular variation underlying this heterogeneity, we profiled gene expression in 62 primary prostate tumors, as well 41 normal specimens and nine lymph node metastases, using cDNA microarrays containing ≈26,000 genes. Unsupervised hierarchical clustering readily distinguished tumors samples, further identified three...
Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the and safety of pembrolizumab in three parallel cohorts a larger mCRPC population.
We report a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA and proteomics phosphoproteomics profiling, of 218 tumors across 7 histological types childhood brain cancer: low-grade glioma (n = 93), ependymoma (32), high-grade (25), medulloblastoma (22), ganglioglioma (18), craniopharyngioma (16), atypical teratoid rhabdoid tumor (12). Proteomics data identify common biological themes that span boundaries, suggesting treatments used for one type may be applied...
Abstract Prostate cancer is clinically heterogeneous, ranging from indolent to lethal disease. Expression profiling previously defined three subtypes of prostate cancer, one (subtype-1) linked favorable behavior, and the others (subtypes-2 -3) with a more aggressive form To explore disease heterogeneity at genomic level, we carried out array-based comparative hybridization (array CGH) on 64 tumor specimens, including 55 primary tumors 9 pelvic lymph node metastases. Unsupervised cluster...
Abstract Prostate cancer is the most common among men in United States, and aberrant DNA methylation known to be an early molecular event its development. Here, we have used expression profiling identify novel hypermethylated genes whose induced by treatment of prostate cell lines with methyltransferase inhibitor 5-Aza-2′-deoxycytidine (5-aza-dC). Of 271 that were 5-aza-dC treatment, 25 also displayed reduced primary tumors compared normal tissue, decreased only one gene, aldehyde...
This study aimed to identify biomarkers for estimating the overall and prostate cancer (PCa)-specific survival in PCa patients at diagnosis. To explore importance of embryonic stem cell (ESC) gene signatures, we identified 641 ESC predictors (ESCGPs) using published microarray data sets. ESCGPs were selected a stepwise manner, combined with reported genes. Selected genes analyzed by multiplex quantitative polymerase chain reaction fine-needle aspiration samples taken diagnosis from Swedish...
Cadherins (CDH) are cell adhesion molecules and their dysfunctions have been implicated in the development of cancer metastases. Several cadherin genes tandemly located on 16q, which is frequently deleted prostate cancer. We therefore used 22 markers 16q to localize important regions metastases this tumor. found deletions 24/32 (75%) tumors. All lymph node brain showed extensive deletions, while 52% primary tumors displayed limited deletions. Commonly (CDRs) 16q23-24, CDR2 (D16S515-D16S516)...
We used comparative genomic hybridization to analyze 17 tumor samples from 11 patients with papillary renal cell carcinoma (RCC), including three hereditary RCC. Whereas the most frequent aberrations confirmed data obtained by banding analyses, copy number increases on 5q, which previously were considered characteristic of nonpapillary RCC, identified in two cases. In complex cases belonging same family, a pattern chromosomal was found: five six imbalances present less case included...
Genetic polymorphisms and expression of steroid receptors may explain why some individuals are more at risk developing prostate cancer. Some factors often discussed androgen stimulation, vitamin A D deficiency. Long CAG-repeats in exon 1 the receptor (AR) gene on X chromosome seem to have a protective role against overstimulation. Likewise, long alleles poly-A tract prevent stimulation.Blood samples from 59 Swedish patients with sporadic cancers, hereditary cancer, 34 Japanese cancer were...
Docetaxel has been the standard first-line therapy in metastatic castration resistant prostate cancer. The survival benefit is, however, limited by either primary or acquired resistance. In this study, Du145 cancer cells were converted to docetaxel-resistant Du145-R and Du145-RB vitro culturing. Next generation RNAseq was employed analyze these cell lines. Forty-two genes identified have mutations after resistance development, of which thirty-four found published sequencing studies using...
BACKGROUND Deletion of chromosome 16q is a frequent aberration in prostatic carcinoma, indicating the existence candidate tumor suppressor genes involved pathogenesis prostate cancer. METHODS Chromosome 16 numerical and loss were studied by fluorescence situ hybridization 31 primary 22 metastatic tumors from 53 patients. The results compared with E-cadherin expression, grade stage, DNA ploidy. RESULTS Numerical aberrations, deletion, expression found 29%, 35%, 29% tumors, respectively, 73%,...
Previous studies in hereditary and sporadic prostate cancer have indicated the existence of a tumor suppressor gene chromosomal region 19p13. The BRG1 this is one possible candidates, based on both frequency inactivating mutations human cell lines, including line DU145, its functional properties. To our knowledge, no been done to evaluate involvement clinical cancer. accomplish this, we carried out complete mutation analysis all 35 exons constitutional DNA samples from 21 patients. We report...
Previous studies have shown that short CAG repeats in the androgen receptor (AR) gene are associated with increased risk of prostate cancer. It is unclear if this association due to linkage disequilibrium a susceptibility locus or directly linked possible functional impact length repeats. In study, number AR was determined cancer patients, benign prostatic hyperplasia (BPH) and controls both Swedish Japanese men. Prostate patients included 59 hereditary, sporadic 33 cases. BPH 38 Controls 98...
Predicting the prognosis of prostate cancer disease through gene expression analysis is receiving increasing interest. In many cases, such analyses are based on formalin-fixed, paraffin embedded (FFPE) core needle biopsy material which Gleason grading for diagnosis has been conducted. Since each patient typically multiple samples, and since an operator dependent procedure known to be difficult, impact operator's choice was evaluated.Multiple samples from 43 patients were evaluated using a...
Background A previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall cancer-specific survivals at diagnosis prostate cancer a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples. Methods We carried out new with 241 patients diagnosed from 2004–2007 follow-up exceeding 6 years order verify the gene formalin fixed paraffin embedded (FFPE) core needle biopsy tissue The consisted...
MUC1 is expressed on the apical surface of glandular epithelium. With functions including protection, adhesion and signaling, has been implicated in prostate cancer. There are many splice variants, best characterized which MUC1/1 MUC1/2 determined by a SNP (rs4072037, 3506G>A). Blood DNA from general population, BPH, sporadic hereditary cancer subjects were genotyped for rs4072037 SNP. G allele frequencies significantly reduced (15%) compared to BPH or samples (27%, 39% 26% respectively)....